A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2009
03/25/2009	CN101390868A Plant polysaccharide and preparation method and use thereof
03/25/2009	CN101390867A Compositions and methods for the treatment of infection
03/25/2009	CN101390864A Specific medicine capable of curing cold after three or four days
03/25/2009	CN101390863A Tinea corporis itching-relieving tincture formulation and manufacture method thereof
03/25/2009	CN101390861A Solid medicine composition containing voriconazole
03/25/2009	CN101390851A Double-cyclitol medicine composition containing surfactant and preparation method thereof
03/25/2009	CN101390848A Medicine composition azithromycin enteric-coated capsules and preparation method thereof
03/25/2009	CN101390847A Ampicillin capsule and production method thereof
03/25/2009	CN101390846A Amoxicillin capsule and production method thereof
03/25/2009	CN101390841A Sitafloxacin hydrate tablet and preparation method thereof
03/25/2009	CN101390837A Amoxicillin granule and production method thereof
03/25/2009	CN101390836A Antifungal activity ophthalmopathy slow-release microparticle and use thereof
03/25/2009	CN101390835A Ribavirin soluble powder
03/25/2009	CN101390825A Intra-ocular release system of voriconazole
03/25/2009	CN100471957C Adenovirus vectors for immunotherapy
03/25/2009	CN100471945C Novel avian disease bacteria and bacterin derived therefrom
03/25/2009	CN100471869C Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of coriolus versicolor
03/25/2009	CN100471857C Purine derivatives
03/25/2009	CN100471856C Bicyclic compounds and compostions as PDF inhibitors
03/25/2009	CN100471851C Lignin in dandelion, its bacteria-resisting activity and use for medicine
03/25/2009	CN100471848C Long-chain alkoxy alkyl substituted sialic acid derivatives and preparing method thereof
03/25/2009	CN100471847C Eremophilane containing chlorine atom in Heizituowu and its anti-biotic and cell-toxin activity
03/25/2009	CN100471832C Compound for preparing protease inhibitor
03/25/2009	CN100471501C Treatment and prophylaxis of diseases and infections of pigs and poultry
03/25/2009	CN100471499C Physical bacteria resisting net liquid of human body and the producing technique
03/24/2009	US7507872 Transgenic toll-like receptor 9 (TLR9) mice
03/24/2009	US7507813 Amorphous cefuroxime axetil and preparation process therefore
03/24/2009	US7507803 Optimized multi-epitope constructs and uses thereof
03/24/2009	US7507795 Zcytor17 ligand cytokine; immunostimulators system, and proliferation and/or development of hematopoietic cells in vitro and in vivo; transcription, gene expression, culturing; anticarcinogenic and antiinflammatory agents; diabetes, pancreatitis, inflammatory bowel disease; autoimmune diseases
03/24/2009	US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity
03/24/2009	US7507753 Biaryl compound and use thereof
03/24/2009	US7507726 Antibiotic; bactericides
03/24/2009	US7507564 Tiacumicin production
03/24/2009	US7507542 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression
03/24/2009	US7507417 Glycoproteins; antigens
03/24/2009	US7507416 adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative especially with polyalkenyl ethers of sugars or polyalcohols; heterologus influenza protein
03/24/2009	US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders
03/24/2009	US7507408 Anti hepatitis C virus antibody and uses thereof
03/24/2009	US7507398 Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention
03/24/2009	US7507397 Delivery of muscle relaxants through an inhalation route
03/24/2009	CA2431100C Dihydroindole and tetrahydroquinoline derivatives
03/24/2009	CA2422380C Pyrazole compounds useful as protein kinase inhibitors
03/24/2009	CA2351203C 2,4-disubstituted triazine derivatives with anti hiv activity
03/24/2009	CA2345896C A method of modulating ion channel functional activity
03/24/2009	CA2319099C Compositions and methods of treating keratin-related disorders and conditions
03/24/2009	CA2223513C Betulinic acid derivatives and uses therefor
03/23/2009	CA2701047A1 Antibody against anthrax toxins
03/21/2009	CA2603615A1 Methods of reducing viral infection and kits therefore
03/19/2009	WO2009036157A1 Donor specific antibody libraries
03/19/2009	WO2009036000A2 Methods of treating a microbial infection by modulating rnase-l expression and/or activity
03/19/2009	WO2009035788A1 Alkylsulfonyl-substituted thiazolide compounds
03/19/2009	WO2009035662A1 Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection
03/19/2009	WO2009035553A2 Analogs of tetramic acid
03/19/2009	WO2009035420A1 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
03/19/2009	WO2009035173A1 Composition for preventing virus infection comprising poly-gamma-glutamic acid
03/19/2009	WO2009035156A1 Novel compound, process for production thereof, and use thereof
03/19/2009	WO2009035068A1 Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin- 2-one derivatives
03/19/2009	WO2009035067A1 Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives
03/19/2009	WO2009034945A1 Medicinal agent for disease associated with epstein-barr virus, and method for screening of the medicinal agent
03/19/2009	WO2009034390A1 Heterocyclic derivatives and their use in treating hepatitis c
03/19/2009	WO2009034386A1 Derivatives of adenine and 8-aza-adenine and uses thereof-796
03/19/2009	WO2009034055A1 Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
03/19/2009	WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent
03/19/2009	WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent
03/19/2009	WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent
03/19/2009	WO2009033821A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
03/19/2009	WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
03/19/2009	WO2009033818A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent
03/19/2009	WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
03/19/2009	WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent
03/19/2009	WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
03/19/2009	WO2009033813A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
03/19/2009	WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof
03/19/2009	WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
03/19/2009	WO2009033809A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033808A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
03/19/2009	WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent
03/19/2009	WO2009033805A2 Use of somatostatin-14 as a therapeutic agent
03/19/2009	WO2009033804A2 Use of gamma- endorphin as a therapeutic agent
03/19/2009	WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents
03/19/2009	WO2009033802A2 Antide as a therapeutic agent
03/19/2009	WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent
03/19/2009	WO2009033800A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033799A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent
03/19/2009	WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
03/19/2009	WO2009033796A1 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033793A2 Pentagastrin as a therapeutic agent
03/19/2009	WO2009033792A2 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
03/19/2009	WO2009033791A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033790A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033787A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033786A2 Use of a peptide as a therapeutic agent
03/19/2009	WO2009033785A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
03/19/2009	WO2009033784A2 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
03/19/2009	WO2009033783A2 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis

1 ... 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 ... 1798